AIDS
MCID: HV1006
MIFTS: 80

Hiv-1 (AIDS) malady

Categories: Genetic diseases, Immune diseases

Aliases & Classifications for Hiv-1

Aliases & Descriptions for Hiv-1:

Name: Hiv-1 54 38
Hiv/aids 54 38 41 3
Aids 54 52 3
Aids, Delayed/rapid Progression to 54 13
Hiv1 Infection 54 38
Human Immunodeficiency Virus Type 1, Susceptibility to 29
Rapid Progression to Aids from Hiv1 Infection 54
Human Immunodeficiency Virus I Infection 69
Acquired Immunodeficiency Syndrome 69
Aids, Rapid Progression to 54
Aids, Slow Progression to 54
Hiv-Infection/aids 69
Hiv-1 Viremia 54
Hiv Type 1 54
Hiv1 54

Classifications:



External Ids:

OMIM 54 609423

Summaries for Hiv-1

MedlinePlus : 41 hiv stands for human immunodeficiency virus. it harms your immune system by destroying the white blood cells that fight infection. this puts you at risk for serious infections and certain cancers. aids stands for acquired immunodeficiency syndrome. it is the final stage of infection with hiv. not everyone with hiv develops aids. hiv most often spreads through unprotected sex with an infected person. it may also spread by sharing drug needles or through contact with the blood of an infected person. women can give it to their babies during pregnancy or childbirth. the first signs of hiv infection may be swollen glands and flu-like symptoms. these may come and go within two to four weeks. severe symptoms may not appear until months or years later. a blood test can tell if you have hiv infection. your health care provider can do the test, or you can use a home testing kit. or to find free testing sites, call the national referral hotline at 1-800-cdc-info (1-800-232-4636 in english and en español; 1-888-232-6348 - tty). there is no cure, but there are many medicines that fight hiv infection and lower the risk of infecting others. people who get early treatment can live with the disease for a long time.

MalaCards based summary : Hiv-1, also known as hiv/aids, is related to tuberculosis and hepatitis, and has symptoms including fever and pruritus. An important gene associated with Hiv-1 is CD209 (CD209 Molecule), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Abacavir and Darunavir have been mentioned in the context of this disorder. Affiliated tissues include t cells, monocytes and brain, and related phenotypes are digestive/alimentary and hematopoietic system

OMIM : 54 The pathogenesis of HIV infection and the progression from infection to AIDS vary significantly between exposed... (609423) more...

CDC : 3 Help

Related Diseases for Hiv-1

Diseases related to Hiv-1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 304)
id Related Disease Score Top Affiliating Genes
1 tuberculosis 30.8 CCL2 CD4 IL10
2 hepatitis 30.3 HLA-C IFNG IL10 KIR3DL1
3 hepatitis c virus 30.0 CCR5 CD209 TLR3
4 pulmonary tuberculosis 29.6 CCL11 CCL3 IFNG IL10 IL4R
5 progressive multifocal leukoencephalopathy 11.3
6 kcnq3-related disorders 10.6 APOBEC3G CCR5 CD209 CD4 CXCR4 IFNG
7 anus leiomyosarcoma 10.6 APOBEC3G CCL3 CCR5 CD209 CD4 CXCL12
8 anterior foramen magnum meningioma 10.6 CCL3 CCR5 CD4 IFNG IL10
9 islet cell tumor 10.5 CXCL12 CXCR4 IL10
10 chronic cervicitis 10.5 CCR5 CXCL12 CXCR4
11 osteodysplasty precocious of danks mayne and kozlowski 10.5 CCL3 CCR5 IFNG IL10
12 detrusor sphincter dyssynergia 10.5 CCL2 CCR5 CD4 IFNG IL10
13 ciliary discoordination, due to random ciliary orientation 10.5 CD4 IFNG IL10
14 elephantiasis 10.5 CD4 IFNG IL10
15 advanced sleep phase syndrome, familial, 1 10.5 CCL2 CCL3 CCR5 CD4 IFNG IL10
16 tularemia 10.5 CD4 IFNG IL10
17 proximal symphalangism 10.5 CCL2 CCR5 IFNG IL10
18 rhabdomyosarcoma 10.5 CXCL12 CXCR4 IL10
19 bone angioendothelial sarcoma 10.5 CCL2 CD4 IFNG IL10
20 hereditary alpha tryptasemia syndrome 10.5 CD209 IFNG IL10
21 non-gestational choriocarcinoma 10.5 CXCR4 IFNG IL10
22 pigmentation disease 10.5 CCL2 CCL3 IFNG IL10
23 complex regional pain syndrome 10.5 CCL2 CCL3 IFNG IL10
24 motor peripheral neuropathy 10.5 CD4 IFNG IL10
25 anal atresia, hypospadias, and penoscrotal inversion 10.5 CCL2 CD209 IFNG
26 autosomal recessive congenital methemoglobinemia 10.5 CXCR4 HLA-C IFNG
27 oral cavity carcinoma in situ 10.5 CCL2 IFNG IL10
28 epithelioid type angiomyolipoma 10.5 CCL2 CCR5 CD4 IFNG
29 orbital osteomyelitis 10.5 HLA-C IFNG IL10
30 causalgia 10.5 CX3CR1 IFNG IL10
31 balkan nephropathy 10.5 CD4 IFNG IL10
32 subcorneal pustular dermatosis 10.5 CCL2 CCL3 IFNG IL10
33 hyperimmunoglobulin syndrome 10.5 CCL2 CD209 IFNG
34 neuroblastoma 10.5
35 retinal ischemia 10.5 CCL2 CCR5 IFNG
36 endometrial transitional cell carcinoma 10.5 CCL2 CD209 IFNG IL10
37 inflammatory bowel disease 2 10.4 CD209 IFNG IL10
38 benign eccrine breast spiradenoma 10.4 CD209 IFNG IL10
39 hallucinogen dependence 10.4 CCR5 IFNG IL10
40 exophthalmos 10.4 CCL3 CCR5 CD209 CD4 CXCR4 IFNG
41 argentine hemorrhagic fever 10.4 CCR5 CD209 IL10 TLR3
42 nonspecific interstitial pneumonia 10.4 CD4 IFNG IL10
43 vestibule of mouth cancer 10.4 CD4 IL10 TLR3
44 depressed scar 10.4 CD209 IFNG IL10 TLR3
45 paralytic poliomyelitis 10.4 CCL3 IFNG TLR3
46 aortic aneurysm, familial thoracic 6 10.4 CCL2 CCL3 CXCL12 IFNG
47 plantar fasciitis 10.4 CCL2 CCR5 CD209 TLR3
48 streptococcal meningitis 10.4 CCL2 CX3CR1 TLR3
49 foodborne botulism 10.4 CD4 IFNG IL10
50 sclerosing adenosis of breast 10.3 CCL2 IFNG IL10

Graphical network of the top 20 diseases related to Hiv-1:



Diseases related to Hiv-1

Symptoms & Phenotypes for Hiv-1

Clinical features from OMIM:

609423

UMLS symptoms related to Hiv-1:


fever, pruritus

MGI Mouse Phenotypes related to Hiv-1:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 CCR5 CD4 CX3CR1 CXCR4 IFNG IL10
2 hematopoietic system MP:0005397 9.7 CD4 CX3CR1 CXCL12 CXCR1 CXCR4 IFNG
3 immune system MP:0005387 9.4 CCL11 CCL2 CCR5 CD4 CX3CR1 CXCL12

Drugs & Therapeutics for Hiv-1

Drugs for Hiv-1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 540)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abacavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 136470-78-5 65140 441300
2
Darunavir Approved Phase 4,Phase 3,Phase 2,Phase 1 635728-49-3, 206361-99-1 213039
3
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 143491-57-0 60877
4
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
5
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 155213-67-5 392622
6
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147127-20-6 464205
7
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 376348-65-1 3002977
8
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
9
Mycophenolic acid Approved Phase 4 24280-93-1 446541
10
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1 30516-87-1 35370
11
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 154598-52-4 64139
12
Rilpivirine Approved Phase 4,Phase 3,Phase 2,Phase 1 500287-72-9
13
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 192725-17-0 92727
14
Cobicistat Approved Phase 4,Phase 3,Phase 2,Phase 1 1004316-88-4
15
Didanosine Approved Phase 4,Phase 3,Phase 2,Phase 1 69655-05-6 50599
16
Nelfinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 159989-64-7 64143
17
Stavudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3056-17-5 18283
18
Amprenavir Approved Phase 4,Phase 3,Phase 2,Phase 1 161814-49-9 65016
19
Rifabutin Approved Phase 4,Phase 2,Phase 1 72559-06-9 6323490
20
Nevirapine Approved Phase 4,Phase 3,Phase 2,Phase 1 129618-40-2 4463
21 Dolutegravir Approved Phase 4,Phase 3,Phase 2,Phase 1 1051375-16-6 54726191
22
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
23
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1 36791-04-5 37542
24
Enfuvirtide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159519-65-0 16130199
25
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 198153-51-4 5360545
26
Fosamprenavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 226700-79-4 131536
27
Indinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 150378-17-9 5362440
28
Rifampin Approved Phase 4,Phase 3,Phase 2,Phase 1 13292-46-1 5458213 5381226
29
Tipranavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174484-41-4 65027
30
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 1 93-14-1 3516
31
Methadone Approved Phase 4,Phase 1 76-99-3 4095
32
Etravirine Approved Phase 4,Phase 3,Phase 2,Phase 1 269055-15-4 193962
33
Atovaquone Approved Phase 4 95233-18-4 74989
34
Proguanil Approved Phase 4 500-92-5 4923
35
Saquinavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 127779-20-8 60787
36
Losartan Approved Phase 4,Phase 2 114798-26-4 3961
37
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
38
Delavirdine Approved Phase 4,Phase 3,Phase 2 136817-59-9 5625
39
Zalcitabine Approved Phase 4,Phase 2,Phase 3 7481-89-2 24066
40
Hydroxyurea Approved Phase 4,Phase 2,Phase 1 127-07-1 3657
41
Sorbitol Approved Phase 4 50-70-4 5780
42
Bleomycin Approved Phase 4,Phase 3 11056-06-7 5360373
43
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 1 23214-92-8 31703
44
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
45
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 1 53-03-2 5865
46
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 52485-79-7 40400 644073
47
Ethambutol Approved Phase 4,Phase 2,Phase 3 74-55-5 3279 14052
48
Isoniazid Approved Phase 4,Phase 2,Phase 3,Phase 1 54-85-3 3767
49
Pyrazinamide Approved Phase 4,Phase 3,Phase 2 98-96-4 1046
50
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 1,Phase 2 99210-65-8, 215647-85-1

Interventional clinical trials:

(show top 50) (show all 1952)
id Name Status NCT ID Phase
1 A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
2 Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts Unknown status NCT01928407 Phase 4
3 Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 Unknown status NCT01235013 Phase 4
4 Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients Unknown status NCT01013987 Phase 4
5 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4
6 Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4
7 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients Unknown status NCT01017172 Phase 4
8 A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients Unknown status NCT00199121 Phase 4
9 Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects Unknown status NCT02042001 Phase 4
10 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4
11 PI Vs. NNRTI Based Therapy for HIV Advanced Disease Unknown status NCT00162643 Phase 4
12 Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects Unknown status NCT02404233 Phase 4
13 Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs Unknown status NCT00005000 Phase 4
14 Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment Unknown status NCT00005017 Phase 4
15 A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients. Unknown status NCT01736761 Phase 4
16 Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs Unknown status NCT00011895 Phase 4
17 Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT) Unknown status NCT01230580 Phase 4
18 SHARE: Simple HAART With Abacavir, Reyataz, and Epivir Unknown status NCT00426296 Phase 4
19 Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients Unknown status NCT01059422 Phase 4
20 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4
21 Computerized Counseling to Promote Positive Prevention and HIV Health in Kenya Unknown status NCT01015989 Phase 4
22 Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity Unknown status NCT02285374 Phase 4
23 Maraviroc Abacavir STudy - Effect on Endothelial Recovery Unknown status NCT01389063 Phase 4
24 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4
25 Simplification From Protease Inhibitors to Raltegravir Unknown status NCT00941083 Phase 4
26 Once Daily 3TC, Efavirenz and ddI for HIV Infection Unknown status NCT00214435 Phase 4
27 Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients Completed NCT01702090 Phase 4
28 Valacyclovir vs. Acyclovir as HSV-2 Suppressive Therapy: Effect on Plasma HIV-1 Levels Among HIV-1/HSV-2 Co-infected Persons Completed NCT01026454 Phase 4
29 Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada Completed NCT00324649 Phase 4
30 Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients Completed NCT01989910 Phase 4
31 Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients Completed NCT00106379 Phase 4
32 HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain Completed NCT00685191 Phase 4
33 Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy Completed NCT01116817 Phase 4
34 Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1—Infected Patients Completed NCT01332227 Phase 4
35 BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1. Completed NCT00326963 Phase 4
36 Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults Completed NCT02246998 Phase 4
37 Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients Completed NCT00365612 Phase 4
38 A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE) Completed NCT01102972 Phase 4
39 ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial Completed NCT00772902 Phase 4
40 Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients Completed NCT01274780 Phase 4
41 Safety and Efficacy Study of Switching From Epzicom to Truvada Completed NCT00724711 Phase 4
42 Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects Completed NCT00884858 Phase 4
43 ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla Completed NCT00615745 Phase 4
44 Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients Completed NCT00287677 Phase 4
45 Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia Completed NCT01378910 Phase 4
46 Immune Response to HPV Vaccine Among HIV-1-infected Subjects in Brazil Completed NCT02236234 Phase 4
47 Pharmacokinetic Study of Interaction Between Nevirapine and Methadone in HIV-1 Infected, Opioid-dependent Adults Completed NCT00273988 Phase 4
48 The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects Completed NCT00540137 Phase 4
49 A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection Completed NCT02569502 Phase 4
50 BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection Completed NCT00337701 Phase 4

Search NIH Clinical Center for Hiv-1

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hiv-1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hiv-1:
AGS-004, electroporated mature dendritic cells for HIV
Embryonic/Adult Cultured Cells Related to Hiv-1:
Maturated and electroporated dendritic cells PMIDs: 20636001

Genetic Tests for Hiv-1

Genetic tests related to Hiv-1:

id Genetic test Affiliating Genes
1 Human Immunodeficiency Virus Type 1, Susceptibility to 29

Anatomical Context for Hiv-1

MalaCards organs/tissues related to Hiv-1:

39
T Cells, Monocytes, Brain, Endothelial, B Cells, Testes, Nk Cells

Publications for Hiv-1

Articles related to Hiv-1:

(show top 50) (show all 6307)
id Title Authors Year
1
HIV controllers exhibit enhanced frequencies of MHC class II tetramer+ Gag-specific CD4+ T cells in chronic clade C HIV-1 infection. ( 28077659 )
2017
2
Identification of a tripartite interaction between the N-terminus of HIV-1 Vif and CBFI^ that is critical for Vif function. ( 28302150 )
2017
3
Molecular epidemiology of HIV-1 in Iceland: Early introductions, transmission dynamics and recent outbreaks among injection drug users. ( 28082188 )
2017
4
Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics study. ( 28086981 )
2017
5
Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor. ( 28521215 )
2017
6
Molecular Dynamics and MM/GBSA integrated protocol probing the correlation between biological activities and binding free energies of HIV-1 TAR RNA inhibitors. ( 28081678 )
2017
7
Conformational dynamics of the frameshift stimulatory structure in HIV-1. ( 28522581 )
2017
8
Mapping Region of Human Restriction Factor APOBEC3H Critical for Interaction with HIV-1 Vif. ( 28336404 )
2017
9
Association of single nucleotide polymorphisms of APOBEC3G with susceptibility to HIV-1 infection and disease progression among men engaging in homosexual activity in northern China. ( 27730383 )
2017
10
Immune regulator ABIN1 suppresses HIV-1 transcription by negatively regulating the ubiquitination of Tat. ( 28193275 )
2017
11
Enhancing the Catalytic Deamination Activity of APOBEC3C Is Insufficient to Inhibit Vif-Deficient HIV-1. ( 28315663 )
2017
12
Haplotypes in CCR5-CCR2, CCL3 and CCL5 are associated with natural resistance to HIV-1 infection in a Colombian cohort. ( 28527291 )
2017
13
Ritonavir and Topical Ocular Corticosteroid Induced Cushing's Syndrome in an Adolescent with HIV-1 Infection. ( 28060049 )
2017
14
"Expand and Click": A New Method for Labeling HIV-1 Envelope Glycoproteins. ( 28525770 )
2017
15
TCR Clonotype-specific Differences in Inhibitory Activity of HIV-1 Cytotoxic T Cell Clones is Not Mediated by TCR Alone. ( 28077649 )
2017
16
Correction to Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120. ( 28517931 )
2017
17
Associations of CD4+ T-cell count, HIV-1 RNA viral load, and antiretroviral therapy with Kaposi sarcoma risk among HIV-infected persons in the United States and Canada. ( 28394855 )
2017
18
HIV-1 viral load measurement in venous blood and fingerprick blood using Abbott RealTime HIV-1 DBS assay. ( 28531553 )
2017
19
Ultrasensitive HIV-1 p24 detects single infected cells and differences in reservoir induction by latency-reversal agents. ( 28077644 )
2017
20
CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance InA Vivo. ( 28527722 )
2017
21
Impact of HIV-1 Integrase L74F/V75I Mutations from a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors. ( 28533248 )
2017
22
Removal of ribonucleotides by p53 protein incorporated during DNA synthesis by HIV-1 reverse transcriptase. ( 28081035 )
2017
23
Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif. ( 28084464 )
2017
24
Efficient Vpu-mediated tetherin antagonism by an HIV-1 group O strain. ( 28077643 )
2017
25
HIV-1 Infection in Persons Homozygous for CCR5-I932 Allele: The Next Case and the Review. ( 28534889 )
2017
26
Update on Recent Developments in Small Molecular HIV-1 RNase H Inhibitors (2013-2016): Opportunities and Challenges. ( 28088905 )
2017
27
Sensitive next generation sequencing method reveals deep genetic diversity of HIV-1 in the Democratic Republic of the Congo. ( 28077647 )
2017
28
A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infection. ( 27652980 )
2017
29
High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay. ( 28529033 )
2017
30
SUN2 silencing impairs CD4 T cell proliferation and alters sensitivity to HIV-1 infection independently of Cyclophilin A. ( 28077629 )
2017
31
Conserved residues within the HIV-1 Vpu transmembrane-proximal hinge region modulate BST2 binding and antagonism. ( 28288652 )
2017
32
Double-winged 3-Hydroxypyrimidine-2,4-diones: Potent and Selective Inhibition against HIV-1 RNase H with Significant Antiviral Activity. ( 28525279 )
2017
33
Reduced Frequency of Cells Latently Infected with Replication-Competent HIV-1 in Virally Suppressed Individuals Living in Rakai, Uganda. ( 28535179 )
2017
34
A review of transition experiences in perinatally and behaviourally acquired HIV-1 infection; same, same but different? ( 28530044 )
2017
35
Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART. ( 28527342 )
2017
36
Characterizing HIV-1 Splicing Using Next Generation Sequencing. ( 28077653 )
2017
37
I36Ta89T mutation in South African subtype C (C-SA) HIV-1 protease significantly alters protease-drug interactions. ( 28525359 )
2017
38
HIV-1 Nef is released in extracellular vesicles derived from astrocytes: evidence for Nef-mediated neurotoxicity. ( 28079886 )
2017
39
The myxobacterial metabolite Soraphen A inhibits HIV-1 by reducing virus production and altering virion composition. ( 28533249 )
2017
40
Reassessing APOBEC3G Inhibition by HIV-1 Vif-Derived Peptides. ( 27887868 )
2017
41
Clinical and Mucosal Immune Correlates of HIV-1 Semen Levels in Antiretroviral-Naive Men. ( 28534034 )
2017
42
Capsid-Dependent Host Factors in HIV-1 Infection. ( 28528781 )
2017
43
HIV-1 DNA dynamics and variations in HIV-1 DNA protease and reverse transcriptase sequences in multidrug-resistant patients during successful raltegravir-based therapy. ( 27197719 )
2016
44
Prolonged persistence of a novel replication-defective HIV-1 variant in plasma of a patient on suppressive therapy. ( 27655142 )
2016
45
Design, synthesis and biological evaluation of (E)-3,4-dihydroxystyryl 4-acylaminophenethyl sulfone, sulfoxide derivatives as dual inhibitors of HIV-1 CCR5 and integrase. ( 28082070 )
2016
46
The protein arginine methyltransferase PRMT6 inhibits HIV-1 Tat nucleolar retention. ( 26611710 )
2016
47
Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. ( 27658864 )
2016
48
New insights into the interaction between pyrrolyl diketoacids and HIV-1 integrase active site and comparison with RNase H. ( 27659398 )
2016
49
Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. ( 27199430 )
2016
50
HIV-1 Nucleocapsid Mimics the Membrane Adaptor Syntenin PDZ to Gain Access to ESCRTs and Promote Virus Budding. ( 26962944 )
2016

Variations for Hiv-1

ClinVar genetic disease variations for Hiv-1:

6 (show all 13)
id Gene Variation Type Significance SNP ID Assembly Location
1 KIR3DL1 KIR3DS, KIR3DS +/- HLA-B Bw4-80ILE undetermined variant Pathogenic
2 CD209 CD209, -336A-G single nucleotide variant protective,risk factor
3 CCR5 NM_000579.3(CCR5): c.554_585del32 (p.Ser185Ilefs) deletion protective,risk factor rs333 GRCh37 Chromosome 3, 46414947: 46414978
4 CCR5 NM_000579.3(CCR5): c.303T> A (p.Cys101Ter) single nucleotide variant protective rs1800560 GRCh37 Chromosome 3, 46414696: 46414696
5 CCR5 NM_000579.3(CCR5): c.-301+246A> G single nucleotide variant protective rs1799987 GRCh37 Chromosome 3, 46411935: 46411935
6 CCR5 NM_000579.3(CCR5): c.180G> T (p.Arg60Ser) single nucleotide variant protective rs1800940 GRCh37 Chromosome 3, 46414573: 46414573
7 CCR2 NM_001123041.2(CCR2): c.190G> A (p.Val64Ile) single nucleotide variant protective rs1799864 GRCh37 Chromosome 3, 46399208: 46399208
8 CCL11 CCL11, -1385G-A single nucleotide variant protective
9 CXCL12 NM_000609.6(CXCL12): c.266+535G> A single nucleotide variant protective rs387906400 GRCh37 Chromosome 10, 44873550: 44873550
10 CCL2 CCL2, -2136A-T single nucleotide variant protective
11 CCL2 CCL2, 767C-G single nucleotide variant protective
12 IL10 IL10, -592C-A single nucleotide variant protective,risk factor
13 TLR3 NM_003265.2(TLR3): c.1234C> T (p.Leu412Phe) single nucleotide variant protective rs3775291 GRCh37 Chromosome 4, 187004074: 187004074

Copy number variations for Hiv-1 from CNVD:

7 (show all 23)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13736 1 1 247249719 Copy number HIV/AIDS
2 74031 13 1 114142980 Copy number HIV/AIDS
3 107129 17 1225928 31649829 Copy number CCL3L3 HIV/AIDS
4 107135 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
5 107136 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
6 107137 17 1225928 31649843 Copy number CCL3L1 HIV/AIDS
7 107145 17 1225928 31649843 Segmental duplicatio ns CCL3L1 HIV/AIDS
8 107159 17 1242109 31665953 Copy number CCL4L2 HIV/AIDS
9 110228 17 31562580 31665959 Copy number CCL4L1 HIV/AIDS
10 110279 17 31800000 38100000 Copy number CCL3L1 HIV/AIDS
11 110285 17 31800000 38100000 Copy number CCL4L1 HIV/AIDS
12 110286 17 31800000 38100000 Copy number CCL4L1 HIV/AIDS
13 110848 17 34522267 34625730 Copy number CCL3L1 HIV/AIDS
14 111275 17 35400000 35600000 Copy number CCL3L1 HIV/AIDS
15 112166 17 38100000 38400000 Copy number CCL3L1 HIV/AIDS
16 112167 17 38100000 38400000 Copy number CCL3L1 HIV/AIDS
17 112170 17 38100000 38400000 Loss CCL3L1 HIV/AIDS
18 179925 4 1 191273063 Copy number HIV/AIDS
19 209403 6 2614953 31491069 Copy number MICA HIV/AIDS
20 211349 6 32593131 32665540 Copy number HLA-DRB5 HIV/AIDS
21 212276 6 3674895 32665540 Copy number HLA-DRB1 HIV/AIDS
22 212425 6 3795995 32719407 Copy number HLA-DQA1 HIV/AIDS
23 212441 6 3813334 32742444 Copy number HLA-DQB1 HIV/AIDS

Expression for Hiv-1

LifeMap Discovery
Genes differentially expressed in tissues of Hiv-1 patients vs. healthy controls: 35 (show all 32)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 RBM25 RNA binding motif protein 25 Blood - 4.35 0.000
2 UBXN4 UBX domain protein 4 Blood - 4.25 0.000
3 LUC7L3 LUC7-like 3 pre-mRNA splicing factor Blood - 4.07 0.000
4 DKC1 dyskeratosis congenita 1, dyskerin Blood - 4.00 0.000
5 XIST X inactive specific transcript (non-protein coding) Lymph - 3.89 0.000
6 SYNCRIP synaptotagmin binding, cytoplasmic RNA interacting protein Blood - 3.79 0.000
7 AP3D1 adaptor-related protein complex 3, delta 1 subunit Blood - 3.77 0.000
8 SRRM2 serine/arginine repetitive matrix 2 Blood - 3.74 0.000
9 SON SON DNA binding protein Blood - 3.73 0.000
10 PTPRC protein tyrosine phosphatase, receptor type, C Blood - 3.67 0.000
11 NKTR natural killer cell triggering receptor Blood - 3.57 0.000
12 ESF1 ESF1 nucleolar pre-rRNA processing protein homolog Blood - 3.53 0.000
13 RBL2 retinoblastoma-like 2 Blood - 3.49 0.000
14 ADAM28 ADAM metallopeptidase domain 28 Blood - 3.48 0.000
15 PNISR PNN-interacting serine/arginine-rich protein Blood - 3.44 0.000
16 HSP90AA1 heat shock protein 90kDa alpha (cytosolic), class A member 1 Blood - 3.38 0.000
17 SCAF11 SR-related CTD-associated factor 11 Blood - 3.36 0.000
18 NBPF10 neuroblastoma breakpoint family, member 10 Blood - 3.35 0.000
19 PRRC2C proline-rich coiled-coil 2C Blood - 3.32 0.000
20 LRRN3 leucine rich repeat neuronal 3 Blood - 3.28 0.000
21 PPIG peptidylprolyl isomerase G (cyclophilin G) Blood - 3.27 0.000
22 IFI27 interferon, alpha-inducible protein 27 Blood + 3.25 0.000
23 TRIM23 tripartite motif containing 23 Blood - 3.23 0.000
24 ANKRD12 ankyrin repeat domain 12 Blood - 3.22 0.000
25 EIF1AY eukaryotic translation initiation factor 1A, Y-linked Lymph + 3.18 0.000
26 CHD4 chromodomain helicase DNA binding protein 4 Blood - 3.12 0.000
27 TNFAIP2 tumor necrosis factor, alpha-induced protein 2 Blood - 3.11 0.000
28 PTMA prothymosin, alpha Blood - 3.10 0.000
29 USO1 USO1 vesicle transport factor Blood - 3.09 0.000
30 ATRX alpha thalassemia/mental retardation syndrome X-linked Blood - 3.06 0.000
31 PRMT2 protein arginine methyltransferase 2 Blood - 3.04 0.000
32 TBL1X transducin (beta)-like 1X-linked Blood - 3.03 0.000
Search GEO for disease gene expression data for Hiv-1.

Pathways for Hiv-1

Pathways related to Hiv-1 according to GeneCards Suite gene sharing:

(show all 37)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14 CCL11 CCL2 CCL3 CCL3L1 CCR5 CD209
2
Show member pathways
13.84 CCL11 CCL2 CCL3 CCL3L1 CCR5 CD4
3
Show member pathways
13.52 CCL11 CCL2 CCL3 CCL3L1 CD4 CXCL12
4
Show member pathways
13.52 CCL11 CCL2 CCL3 CCL3L1 CCR5 CD4
5
Show member pathways
13.38 CCL11 CCL2 CCL3 CCL3L1 CCR5 CXCL12
6
Show member pathways
13.32 CCL11 CCL2 CCL3 CCL3L1 CCR5 CD4
7
Show member pathways
13.1 CCL11 CCL2 CCL3 CCL3L1 CCR5 CD4
8
Show member pathways
12.91 CCL11 CCL2 CCL3 CCL3L1 CCR5 CD4
9
Show member pathways
12.89 CCL2 CCL3 CCL3L1 IFNG IL10 TLR3
10
Show member pathways
12.78 CCL11 CD4 CXCL12 CXCR4 HLA-C IFNG
11
Show member pathways
12.75 CCL2 CD209 HLA-C IFNG TLR3
12
Show member pathways
12.61 CCL11 CCL2 CCL3 CCL3L1 CCR5 CD4
13 12.52 CCL2 CXCL12 CXCR4 IFNG IL10 TLR3
14 12.39 CCR5 CXCR1 CXCR4 HLA-C
15
Show member pathways
12.38 CCR5 CD4 IFNG IL10
16 11.99 CD209 CD4 CX3CR1 IFNG IL10
17 11.98 CCL11 CCL2 IL10 IL4R
18
Show member pathways
11.97 CCL3 CCR5 CD4 IFNG
19
Show member pathways
11.94 CD4 IFNG IL10 TLR3
20
Show member pathways
11.91 CD4 IFNG IL4R TLR3
21 11.85 CCL2 CCL3 CCL3L1 CXCL12 IFNG
22 11.79 CCR5 CXCR4 IL4R
23 11.78 CCL3 CD4 IFNG IL10
24 11.77 CCL3 CCL3L1 IFNG
25 11.74 CD209 CD4 CX3CR1 IFNG IL10
26 11.71 CD4 CXCL12 CXCR4
27 11.69 CXCL12 CXCR4 IFNG IL10
28 11.63 CCL11 IL10 IL4R
29 11.62 CCL11 CCL2 CCL3
30 11.56 CD4 CXCR4 IL10 IL4R
31 11.5 CCL2 IFNG IL10
32 11.49 CCL2 CCL3 CCL3L1 CCR5 IL10
33
Show member pathways
11.41 CCL3 IFNG IL10
34 11.39 CCL11 CD4 IFNG IL10 IL4R
35
Show member pathways
11.37 CCL11 CCL2 CCL3 CCL3L1 CCR5 CX3CR1
36 11.26 CD4 IFNG IL10
37 11.18 CCL11 CCL2 CCL3 CCL3L1 CXCL12 IL10

GO Terms for Hiv-1

Cellular components related to Hiv-1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 CCL11 CCL2 CCL3 CCL3L1 CD209 CXCL12
2 extracellular space GO:0005615 9.76 CCL11 CCL2 CCL3 CCL3L1 CXCL12 IFNG
3 cell surface GO:0009986 9.43 CCR5 CD209 CD4 CXCR4 HLA-C TLR3
4 external side of plasma membrane GO:0009897 9.02 CCR5 CD209 CD4 CXCL12 IFNG

Biological processes related to Hiv-1 according to GeneCards Suite gene sharing:

(show all 43)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.99 CCL11 CCL2 CCL3 CCL3L1 CD4
2 cellular response to tumor necrosis factor GO:0071356 9.93 CCL11 CCL2 CCL3 CCL3L1
3 cellular calcium ion homeostasis GO:0006874 9.92 CCL11 CCL2 CCL3 CXCL12
4 cellular response to lipopolysaccharide GO:0071222 9.92 CCL2 CCR5 CX3CR1 IFNG IL10
5 cellular response to interleukin-1 GO:0071347 9.91 CCL11 CCL2 CCL3 CCL3L1
6 inflammatory response GO:0006954 9.91 CCL11 CCL2 CCL3 CCL3L1 CCR5 CXCR1
7 positive regulation of endothelial cell proliferation GO:0001938 9.88 CCL11 CCL2 CXCL12 IL10
8 cell chemotaxis GO:0060326 9.85 CCL2 CCL3 CXCL12
9 positive regulation of tumor necrosis factor production GO:0032760 9.85 CCL2 CCL3 IFNG TLR3
10 response to virus GO:0009615 9.85 CCL11 CXCL12 CXCR4 IFNG TLR3
11 antigen processing and presentation GO:0019882 9.83 CD209 HLA-C IFNG
12 calcium-mediated signaling GO:0019722 9.83 CCL3 CCR5 CXCR4
13 positive regulation of cell adhesion GO:0045785 9.82 CCL2 CXCL12 IFNG
14 chemotaxis GO:0006935 9.81 CCL11 CCL2 CCL3 CCL3L1 CCR5 CX3CR1
15 monocyte chemotaxis GO:0002548 9.8 CCL11 CCL2 CCL3 CCL3L1
16 defense response to protozoan GO:0042832 9.79 IFNG IL10 IL4R
17 positive regulation of calcium ion import GO:0090280 9.78 CCL2 CCL3 CXCL12
18 dendritic cell chemotaxis GO:0002407 9.77 CCR5 CXCR1 CXCR4
19 neutrophil chemotaxis GO:0030593 9.77 CCL11 CCL2 CCL3 CCL3L1 IFNG
20 viral genome replication GO:0019079 9.75 CCL2 CD209 HTATSF1
21 macrophage chemotaxis GO:0048246 9.74 CCL2 CCL3 CX3CR1
22 lymphocyte chemotaxis GO:0048247 9.73 CCL11 CCL2 CCL3 CCL3L1
23 immune response GO:0006955 9.73 CCL11 CCL2 CCL3 CCL3L1 CCR5 CD4
24 cellular response to interferon-gamma GO:0071346 9.72 CCL11 CCL2 CCL3 CCL3L1 TLR3
25 positive regulation of macrophage activation GO:0043032 9.69 IL10 IL4R
26 fusion of virus membrane with host plasma membrane GO:0019064 9.69 CCR5 CD4 CXCR4
27 positive regulation of chemokine biosynthetic process GO:0045080 9.68 IFNG TLR3
28 chronic inflammatory response GO:0002544 9.68 CCL11 CCL2
29 response to cholesterol GO:0070723 9.68 CCL3 CCR5
30 signaling GO:0023052 9.68 CCL3 CCR5
31 eosinophil chemotaxis GO:0048245 9.67 CCL11 CCL3
32 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 IFNG IL10
33 release of sequestered calcium ion into cytosol by sarcoplasmic reticulum GO:0014808 9.66 CCL3 CCR5
34 astrocyte cell migration GO:0043615 9.65 CCL2 CCL3
35 microglial cell activation involved in immune response GO:0002282 9.64 CX3CR1 TLR3
36 entry into host cell GO:0030260 9.58 CCR5 CD4 CXCR4
37 chemokine-mediated signaling pathway GO:0070098 9.28 CCL11 CCL2 CCL3 CCL3L1 CCR5 CX3CR1
38 signal transduction GO:0007165 10.3 CCL11 CCL2 CCR5 CD4 CX3CR1 CXCL12
39 G-protein coupled receptor signaling pathway GO:0007186 10.19 CCL11 CCL2 CCL3 CCL3L1 CCR5 CX3CR1
40 cell adhesion GO:0007155 10.12 CCL11 CCL2 CD209 CD4 CX3CR1 CXCL12
41 immune system process GO:0002376 10.09 APOBEC3G CD209 CD4 HLA-C TLR3
42 cell surface receptor signaling pathway GO:0007166 10.03 CCL2 CCR5 CD4 CXCR1 IFNG
43 viral process GO:0016032 10.02 APOBEC3G CCR5 CD209 CD4 CX3CR1 CXCR4

Molecular functions related to Hiv-1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.56 CCR5 CD209 CD4 CXCR4
2 coreceptor activity GO:0015026 9.5 CCR5 CD4 CXCR4
3 chemokine receptor activity GO:0004950 9.46 CCR5 CX3CR1